Perbak Capital Partners LLP Takes $1.52 Million Position in Qiagen (NYSE:QGEN)

Perbak Capital Partners LLP purchased a new stake in Qiagen (NYSE:QGEN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 34,077 shares of the company's stock, valued at approximately $1,517,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Brown Brothers Harriman & Co. bought a new stake in Qiagen in the fourth quarter valued at approximately $37,000. Geneos Wealth Management Inc. lifted its holdings in Qiagen by 41.5% during the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen in the third quarter valued at $53,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after buying an additional 835 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Trading Up 2.3 %

Shares of QGEN stock traded up $0.95 during mid-day trading on Friday, reaching $43.15. 1,204,867 shares of the stock traded hands, compared to its average volume of 1,123,777. The stock's fifty day simple moving average is $40.28 and its two-hundred day simple moving average is $41.72. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The company has a market cap of $9.59 billion, a price-to-earnings ratio of 120.15, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. On average, research analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on QGEN. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group lowered their price objective on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Robert W. Baird boosted their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Morgan Stanley restated an "equal weight" rating and issued a $46.67 price target (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.